Lilly and Baxter Remain Risk-Mitigated Plays For Alzheimer's Drugs - Reuters

Lilly and Baxter Remain Risk-Mitigated Plays For Alzheimer's Drugs Reuters Tue Aug 7, 2012 10:06am EDT. With the announcement that Elan's (NYSE:ELN) bapineuzumab candidate for Alzheimer's disease failed again in a Phase III clinical trial, partners Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) have decided to pack it ... and more »